Copyright: ©Author(s) 2026.
World J Nephrol. Jun 25, 2026; 15(2): 117719
Published online Jun 25, 2026. doi: 10.5527/wjn.v15.i2.117719
Published online Jun 25, 2026. doi: 10.5527/wjn.v15.i2.117719
Figure 5 Barriers to translating artificial intelligence models into clinical chronic kidney disease care.
Overview of technical, organizational, regulatory, equity, and infrastructure barriers that limit the progression of artificial intelligence models from development to real-world clinical impact in chronic kidney disease care. AUROC: Area under the receiver operating characteristic; AI: Artificial intelligence; FDA: United States Food and Drug Administration; EU: European Union; LMIC: Low-and middle-income countries.
- Citation: Eskandar K. Artificial intelligence in chronic kidney disease: Early detection, risk prediction, and personalized treatment strategies. World J Nephrol 2026; 15(2): 117719
- URL: https://www.wjgnet.com/2220-6124/full/v15/i2/117719.htm
- DOI: https://dx.doi.org/10.5527/wjn.v15.i2.117719